Allan S. Jaffe MDProfessor of Medicine, Cardiovascular Division; Professor and Chair, Division of Clinical Core Laboratory Services, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
Dr. Allan Jaffe is a graduate of the University of Maryland School of Medicine. He received his house staff and Cardiology training at Washington University and continued there for 22 years rising to the rank of Professor of Medicine and Director of the Coronary Care Unit. He then moved to the State University of New York where he was Chair of the Cardiovascular Division, Associate Chair of Medicine for Academic Affairs, and Professor of Medicine. After four years he moved to the Mayo Clinic where he is presently Professor of Medicine in the Cardiovascular Division and Professor and Chair of the Division of Core Clinical Laboratory Services in the Department of Laboratory Medicine and Pathology. He is a noted authority on biomarkers of cardiac injury, inflammation, hemodynamic disturbance, and coagulation and particularly their clinical utility. He has published a large number of original manuscripts, book chapters, reviews, and sits on most of the prestigious editorial boards and guideline committees in the Cardiology and Clinical Chemistry communities.
Disclosure: Dr. Jaffe has, or presently consults for most of the major diagnostic companies.
Dr. Jaffe has or presently consults for most of the major diagnostic companies, including the ones responsible for the assay results in the paper being reviewed (see below).
Direct Comparison of Four Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I
Circulation 3/10/2017;[EPub Ahead of Print], Jasper Boeddinghaus, Thomas Nestelberger, Raphael Twerenbold, Karin Wildi, Patrick Badertscher, Janosch Cupa, Tobias Bürge, Patrick Mächler
Recent Contributions to PracticeUpdate:
- Diagnostic Performance of hs-cTn Strategies and Clinical Variables in a Multisite US Cohort
- Cardiac Procedural Myocardial Injury, Infarction, and Mortality in Patients Undergoing Elective PCI
- Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults
- Type 2 Myocardial Infarction
- Cardiac Troponin Elevation in Patients Without a Specific Diagnosis
- Updated International Guidelines for Defining, Classifying, and Diagnosing Myocardial Infarction
- Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
- Comparison of Four Very Early Rule-Out Strategies for Acute Myocardial Infarction
- High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease
- MY APPROACH to Cardiac Troponin Elevations in Patients With Renal Disease